Publications by authors named "Clive Loveday"

Claim this Profile
T
The global spread of HIV-1 subtype B epidemic.
Gkikas Magiorkinis, Konstantinos Angelis, Ioannis Mamais, Aris Katzourakis, Angelos Hatzakis, Clive Loveday

Infect Genet Evol· December 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparative effectiveness of dried plasma HIV-1 viral load testing in Brazil using ViveST for sample collection.
Michelle Zanoni, Rodrigo Cortes, Ricardo S Diaz, M Cecilia Sucupira, Denise Ferreira, Clive Loveday

J Clin Virol· December 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Resistance and virological response analyses in a three initial treatment strategy trial: a substudy of the INITIO trial.
Diane Descamps, Corine Chazallon, Clive Loveday, Lee Bacheler, Ruth Goodall

HIV Clin Trials· March 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tracing the HIV-1 subtype B mobility in Europe: a phylogeographic approach.
Dimitrios Paraskevis, Oliver Pybus, Gkikas Magiorkinis, Angelos Hatzakis, Annemarie Mj Wensing, Clive Loveday

Retrovirology· May 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of genotypic resistance profiles and virological response between patients starting nevirapine and efavirenz in EuroSIDA.
Wendy P Bannister, Lidia Ruiz, Alessandro Cozzi-Lepri, Amanda Mocroft, Ole Kirk, Clive Loveday

AIDS· January 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tipranavir/T20-based salvage regimens highly effective and durable against HIV-1 with evidence for genotypic predictability of response in clinical practice.
R K Gupta, Clive Loveday, U Kalidindi, M Lechelt, Celia Skinner

Int J STD AIDS· September 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
HIV-1 subtypes and response to combination antiretroviral therapy in Europe.
Wendy P Bannister, Lidia Ruiz, Clive Loveday, Stefano Vella, Kai Zilmer

Antivir Ther· March 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evolution of drug resistance in HIV-infected patients remaining on a virologically failing combination antiretroviral therapy regimen.
Alessandro Cozzi-Lepri, Andrew N Phillips, Lidia Ruiz, Bonaventura Clotet, Clive Loveday

AIDS· March 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Thymidine analogue mutation profiles: factors associated with acquiring specific profiles and their impact on the virological response to therapy.
Alessandro Cozzi-Lepri, Lidia Ruiz, Clive Loveday, Andrew N Phillips, Bonaventura Clotet

Antivir Ther· August 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A randomised trial of subcutaneous intermittent interleukin-2 without antiretroviral therapy in HIV-infected patients: the UK-Vanguard Study.
Mike Youle, Sean Emery, Martin Fisher, Mark Nelson, Lisa Fosdick, Clive Loveday

PLoS Clin Trials· May 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The calculated genetic barrier for antiretroviral drug resistance substitutions is largely similar for different HIV-1 subtypes.
David A van de Vijver, Annemarie M J Wensing, Gioacchino Angarano, Birgitta Asjö, Claudia Balotta, Clive Loveday

J Acquir Immune Defic Syndr· March 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prevalence of drug-resistant HIV-1 variants in untreated individuals in Europe: implications for clinical management.
Annemarie M J Wensing, David A van de Vijver, Gioacchino Angarano, Birgitta Asjö, Claudia Balotta, Clive Loveday

J Infect Dis· September 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long term probability of detection of HIV-1 drug resistance after starting antiretroviral therapy in routine clinical practice.
Andrew N Phillips, David Dunn, Caroline Sabin, Anton Pozniak, Ryanne Matthias, Clive Loveday

AIDS· March 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Baseline resistance and virological outcome in patients with virological failure who start a regimen containing abacavir: EuroSIDA study.
Cecilia Cabrera, Alessandro Cozzi-Lepri, Andrew N Phillips, Clive Loveday, Ole Kirk

Antivir Ther· October 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Extensive antiretroviral therapy resistance in an HIV-infected Zimbabwean patient in the UK.
Elizabeth Foley, Deborah Watson-Jones, Clive Loveday

AIDS· November 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Q
Questions to and answers from the International AIDS Society-USA Resistance Testing Guidelines Panel.
Martin S Hirsch, Françoise Brun-Vézinet, Bonaventura Clotet, Brian Conway, Daniel R Kuritzkes, Clive Loveday

Top HIV Med· October 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Drug resistance mutations in HIV-1.
Richard T D'Aquila, Jonathan M Schapiro, Françoise Brun-Vézinet, Bonaventura Clotet, Brian Conway, Clive Loveday

Top HIV Med· August 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1: 2003 recommendations of an International AIDS Society-USA Panel.
Martin S Hirsch, Françoise Brun-Vézinet, Bonaventura Clotet, Brian Conway, Daniel R Kuritzkes, Clive Loveday

Clin Infect Dis· July 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Theoretical rationale for the use of sequential single-drug antiretroviral therapy for treatment of HIV infection.
Andrew N Phillips, Michael S Youle, Fiona Lampe, Margaret Johnson, Caroline A Sabin, Clive Loveday

AIDS· May 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Viral breakthrough after suppression with highly active antiretroviral therapy: experience from 233 individuals with viral loads of less than 50 copies/ml followed for up to 4 years.
Fiona C Lampe, Margaret A Johnson, Marc Lipman, Clive Loveday, Mike Youle

AIDS· March 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evolution of antiretroviral phenotypic and genotypic drug resistance in antiretroviral-naive HIV-1-infected children treated with abacavir/lamivudine, zidovudine/lamivudine or abacavir/zidovudine, with or without nelfinavir (the PENTA 5 trial).
Diana M Gibb, A Sarah Walker, Steve Kaye, Anita De Rossi, Mounir Ait-Khaled, Clive Loveday

Antivir Ther· December 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Human immunodeficiency virus rebound after suppression to <400 copies/mL during initial highly active antiretroviral therapy regimens, according to prior nucleoside experience and duration of suppression.
Andrew N Phillips, Schlomo Staszewski, Fiona Lampe, Michael S Youle, Stephan Klauke, Clive Loveday

J Infect Dis· October 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CD4 cell count changes in individuals with counts above 500 cells/mm and viral loads below 50 copies/ml on antiretroviral therapy.
Andrew N Phillips, Michael Youle, Fiona Lampe, Caroline A Sabin, Andrew Hill, Clive Loveday

AIDS· May 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Raised viral load in patients with viral suppression on highly active antiretroviral therapy: transient increase or treatment failure?
Antonia L Moore, Mike Youle, Marc Lipman, Alessandro Cozzi-Lepri, Fiona Lampe, Clive Loveday

AIDS· March 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Drug Resistance Mutations in HIV-1.
Richard T. D'Aquila, , Jonathan M. Schapiro, Françoise Brun-Vézinet, Bonaventura Clotet, Clive Loveday

Top HIV Med· January 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis